Recently, Zhejiang Symer Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Baicheng Pharmaceutical Co., Ltd., obtained marketing approval from the State Drug Administration for marketing of Class 2.2 modified new drug levetiracetam sustained-release granules. This is the first improved new drug approved by Baicheng Pharmaceutical, marking a landmark breakthrough in the field of improved new drug research and development.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.